...
首页> 外文期刊>Pathology Research and Practice >Quantitative study of ductal breast cancer progression. A progression index (P.I.) for premalignant lesions and in situ carcinoma.
【24h】

Quantitative study of ductal breast cancer progression. A progression index (P.I.) for premalignant lesions and in situ carcinoma.

机译:乳腺导管癌进展的定量研究。恶变前病变和原位癌的进展指数(P.I.)。

获取原文
获取原文并翻译 | 示例
           

摘要

The diagnostic subjective assessment of ductal premalignant proliferative lesions and in situ carcinoma of the breast produces unsatisfactory results. Since the phenotypical cell changes in tumour progression toward infiltrating cancer constitute a continuum, a grading on a continuous scale of values produces a more reliable and reproducible characterization. The diagnostic assessment for any individual patient may be expressed by a progression index (P.I.): its numerical values are based on the cellular changes measured in the individual cases. In this study, the progression index is based on two morphometric features, nuclear size and nucleolar area. In addition, the method presented may produce a ratio, stating the relative likelihood that each case represents one of the conventional diagnostic categories. Such a likelihood ratio may be obtained from the bivariate distribution of nuclear size and nucleolar area for the conventional diagnostic categories.
机译:乳腺导管癌前增生性病变和原位癌的诊断主观评估结果不理想。由于肿瘤向浸润性癌症发展过程中的表型细胞变化构成了一个连续体,因此以连续的数值范围定级可产生更可靠和可再现的特征。任何患者的诊断评估都可以用进展指数(P.I.)表示:其数值基于在各个病例中测得的细胞变化。在这项研究中,进展指数基于两个形态特征:核大小和核仁面积。此外,提出的方法可能会产生一个比率,说明每种情况代表常规诊断类别之一的相对可能性。对于常规诊断类别,可以从核大小和核仁面积的二元分布中获得这种似然比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号